Crossmark

Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings

Crossref DOI link: https://doi.org/10.1186/s13018-025-06300-2

Published Online: 2025-10-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ugur, Fatih https://orcid.org/0000-0001-6109-8425
Yilmaz, Ibrahim https://orcid.org/0000-0003-2003-6337
Guner, Ersin https://orcid.org/0000-0001-6340-5441
Albayrak, Mehmet https://orcid.org/0000-0002-4074-7024
Taskin, Recep https://orcid.org/0000-0002-3656-6140
Sarikas, Nurtac https://orcid.org/0000-0002-2170-0300
Bildirici, Mehmet Akif https://orcid.org/0000-0003-3062-5856
Dellalbasi, Ayse Basak https://orcid.org/0000-0002-5796-5298
Ozcan, Candemir https://orcid.org/0000-0003-2186-5305
License Information

Text and Data Mining valid from 2025-10-08

Version of Record valid from 2025-10-08
More Information

Article History

Received: 3 August 2025

Accepted: 10 September 2025

First Online: 8 October 2025

Declarations

:

: Ethics approval to use live mammal subjects in the research was obtained from the Kastamonu University Experimental Animals Unit (Date: 10.01.2025, approval number: 2025/1).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below